COVID-19 and non-COVID ARDS patients demonstrate a distinct response to low dose steroids- A retrospective observational study

Since the beginning of the COVID-19 pandemic, Hydroxychloroquine is being prescribed by the doctors all over the world for the treatment as well as prevention of COVID-19 with varying results. As we know damage in severe COVID-19 disease occurs mainly via the immunological mechanism. There is an assumption that HCQ has immunomodulatory property and thus may have a beneficial role in severe COVID-19 disease. In this retrospective study, we describe our experience of using low dose of HCQ (200mg/day) in 27 hospitalized severe cases of COVID-19 disease. We found, though the use of HCQ resulted in improvements in chest X-rays, there was no significant reduction in the deaths in the cases where HCQ was used.

Download Full-text

Association between a low dose of proton pump inhibitors and kidney function decline in elderly hypertensive patients: a retrospective observational study

Journal of International Medical Research ◽

10.1177/03000605211006653 ◽

2021 ◽

Vol 49 (4) ◽

pp. 030006052110066

Author(s):

Tomohito Wakabayashi ◽

Keiko Hosohata ◽

Saki Oyama ◽

Ayaka Inada ◽

Iku Niinomi ◽

...

Keyword(s):

Observational Study ◽

Proton Pump Inhibitors ◽

Proton Pump ◽

Low Dose ◽

Retrospective Observational Study ◽

Cumulative Exposure ◽

High Dose ◽

Hypertensive Patients ◽

Acid Suppression Therapy ◽

Kidney Function Decline

Objectives Proton pump inhibitors (PPIs) are widely used for acid suppression therapy. Recently, PPI use was reported to be associated with chronic kidney disease (CKD); however, whether a low dose of PPIs is associated with CKD remains unknown. Methods This retrospective observational study included hypertensive patients who visited Kenwakai Hospital between 2017 and 2019. Renal parameters, such as the estimated glomerular filtration rate (eGFR) and serum creatinine (Scr), were extracted from medical records and compared between three years before treatment and the baseline. PPI use was assessed as cumulative exposure for three years. Results The study population included 152 patients (57.9% men; mean age, 74.5 years). Of those, 35.5% were PPI users (low dose, 17.1%; high dose, 18.4%). A significant decrease in eGFR and an increase in Scr were observed between three years before treatment and the baseline in the high-dose PPI group but not the non-use or low-dose PPI groups. Conclusions Our results suggest that a low dose of PPIs may be safe in clinical settings, but further prospective studies are needed to clarify our findings.

Download Full-text

Hemmkörperentwicklung bei Hämophilie-Patienten nach Präparate wechsel

Hämostaseologie ◽

10.1055/s-0037-1619773 ◽

2012 ◽

Vol 32 (S 01) ◽

pp. S39-S42 ◽

Cited By ~ 1

Author(s):

S. Kocher ◽

G. Asmelash ◽

V. Makki ◽

S. Müller ◽

S. Krekeler ◽

...

Keyword(s):

Risk Factors ◽

Risk Factor ◽

Observational Study ◽

Retrospective Observational Study ◽

Frequent Change ◽

Patient Age ◽

Treatment Regimens ◽

Patient Âgé ◽

The Relationship ◽

Observation Period

SummaryThe retrospective observational study surveys the relationship between development of inhibitors in the treatment of haemophilia patients and risk factors such as changing FVIII products. A total of 119 patients were included in this study, 198 changes of FVIII products were evaluated. Results: During the observation period of 12 months none of the patients developed an inhibitor, which was temporally associated with a change of FVIII products. A frequent change of FVIII products didn’t lead to an increase in inhibitor risk. The change between plasmatic and recombinant preparations could not be confirmed as a risk factor. Furthermore, no correlation between treatment regimens, severity, patient age and comorbidities of the patients could be found.

Download Full-text